These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18651538)

  • 1. Recombinant human erythropoietins, biosimilars and immunogenicity.
    Schellekens H
    J Nephrol; 2008; 21(4):497-502. PubMed ID: 18651538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of "biosimilars".
    Locatelli F; Becker H
    Oncologist; 2009; 14 Suppl 1():16-21. PubMed ID: 19762513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in erythropoietic agents in renal anemia.
    Macdougall IC
    Semin Nephrol; 2006 Jul; 26(4):313-8. PubMed ID: 16949470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous quality improvement (CQI) in rhu-Epo management: the outcome.
    Descamps C; Van Waeleghem JP; Ysebaert D
    EDTNA ERCA J; 1996; 22(3):22-6. PubMed ID: 10723328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anemia in chronic renal failure and erythropoietin].
    Rosenlöf K
    Duodecim; 1995; 111(15):1489-95. PubMed ID: 9244705
    [No Abstract]   [Full Text] [Related]  

  • 6. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.
    Macdougall IC; Ashenden M
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):117-30. PubMed ID: 19233071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To treat or not to treat renal anemia of chronic kidney disease patients?
    Tsubakihara Y
    Ther Apher Dial; 2010 Jun; 14(3):235-9. PubMed ID: 20609177
    [No Abstract]   [Full Text] [Related]  

  • 8. [Case of early pronounced anemia and its effective treatment with human recombinant erythropoietin in a female patient with polycystic kidney in a conservative stage of chronic renal failure].
    Alekseeva TB; Nikolaev AIu; Trofimova EI
    Ter Arkh; 1999; 71(6):70-1. PubMed ID: 10420463
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing anemia. What do we do now? Views from Canada.
    Mendelssohn DC; Muirhead N; Manns BJ
    Nephrol News Issues; 2007 Jun; 21(7):55-7. PubMed ID: 17623988
    [No Abstract]   [Full Text] [Related]  

  • 10. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in the therapeutic use of erythropoiesis stimulating agents.
    Jelkmann W
    Br J Haematol; 2008 May; 141(3):287-97. PubMed ID: 18410567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [How to optimize the concept of the variability of haemoglobin in dialysis patients].
    Kessler M
    Nephrol Ther; 2008 Dec; 4(7):547-8. PubMed ID: 18809370
    [No Abstract]   [Full Text] [Related]  

  • 13. We are overreacting to our hemoglobin fear.
    Sadler JH
    Nephrol News Issues; 2007 Jun; 21(7):48. PubMed ID: 17623985
    [No Abstract]   [Full Text] [Related]  

  • 14. The EPO/iron marriage: counseling needed.
    Bralow S
    Nephrol News Issues; 2007 Jun; 21(7):53, 55. PubMed ID: 17623987
    [No Abstract]   [Full Text] [Related]  

  • 15. Do hemodialysis patients need higher doses of erythropoietin if given intravenously rather than subcutaneously?
    McMahon LP
    Nat Clin Pract Nephrol; 2006 May; 2(5):246-7. PubMed ID: 16932434
    [No Abstract]   [Full Text] [Related]  

  • 16. Through the looking glass: the protein science of biosimilars.
    Goldsmith D; Kuhlmann M; Covic A
    Clin Exp Nephrol; 2007 Sep; 11(3):191-195. PubMed ID: 17891344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe, life-threatening renal anemia treatment in patients who do not accept heterologous blood transfusion for religious reasons--case report].
    Jaroszyński AJ; Bober-Palak E; Jóźwiak L; Ksiazek A
    Przegl Lek; 2007; 64(7-8):528-30. PubMed ID: 18409359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin in the critically ill: what is the evidence?
    Corwin HL; Eckardt KU
    Nephrol Dial Transplant; 2005 Dec; 20(12):2605-8. PubMed ID: 16221691
    [No Abstract]   [Full Text] [Related]  

  • 19. ESA therapy for anemia management: a call for civil discourse.
    McAllister CJ
    Nephrol News Issues; 2007 Jun; 21(7):49-50. PubMed ID: 17623986
    [No Abstract]   [Full Text] [Related]  

  • 20. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.